Pharmaceutical company BioPharmX Corporation (NYSE American:BPMX) stated on Thursday its net loss of USD4.4m (USD0.02 per share) for the quarter ended 31 October 2018.
This marks a drop in earnings when compared with a lower net loss of USD3.7m (USD0.05 per share) during the prior fiscal year's third quarter.
Revenues of USD10,000 were generated for the third quarter ended 31 October 2018,down over revenues of USD18,000 in the prior fiscal year's third quarter.
Total operating expenses were USD4.4m for the third quarter ended 31 October 2018, a rise versus total operating expenses of USD3.7m in the prior fiscal year's third quarter.
As of 31 October 2018, the cash and cash equivalents were USD3.0m.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva